



SPAFID
CONNECT

Informazione Regolamentata n. 20106-15-2022	Data/Ora Ricezione 23 Febbraio 2022 17:40:24	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA
Identificativo : 157691
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN02 - Lacorte rOBERTO
Tipologia : REGEM
Data/Ora Ricezione : 23 Febbraio 2022 17:40:24
Data/Ora Inizio : 23 Febbraio 2022 17:40:25
Diffusione presunta
Oggetto : PR PHARMANUTRA - Modification
corporate events 2022

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: MODIFICATION OF THE 2022 CORPORATE EVENTS CALENDAR

Pisa, 23rd February 2022 – [PharmaNutra S.p.A.](#) (the “Company”) announces that, pursuant to Article 2.6.2 of the Rules of the Markets organised and managed by Borsa Italiana, the 2022 corporate events calendar is modified as indicated in the table below. However, all the other dates are currently confirmed as per the press release issued on the 14th of January 2022.

Date	Event
March 18 th , 2022	Board of Directors for the examination of the Financial Statements as of 31st December 2021
April 27 th , 2022	Ordinary Shareholders’ Meeting for the approval of the Financial Statements as of 31st December 2021

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by considerable scientific proof. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 130 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in 50 countries abroad, through 32 partners selected from among the finest pharmaceutical companies. Over the years, PharmaNutra has stood out in the production of iron-based nutritional supplements with the trademark SiderAL®, where it can claim important Sucrosomial Technology® patents. The Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-15

Numero di Pagine: 4